A spin-out of Oxford University, ONI's desktop microscopy platform aims to help researchers and life sciences firms zoom in on single molecules in living cells to better develop therapies.
With operations split between San Diego and the U.K., the company’s series B proceeds will help staff up commercial and R&D teams in the U.S. and Asia.
Pioneers in observing single molecules in living cells Funds will be used to build a product portfolio that harnesses the company's innovative technology to unlock new possibilities in therapeutic
Ultivue Announces $50M Financing Round
on April 28 2021 12:07 AM
CAMBRIDGE, Mass. (BUSINESS WIRE) Ultivue, a leader in advancing precision medicine solutions through a unique approach that combines multiplex biomarker analysis with same slide traditional H&E for tissue phenotyping, today announced the completion of a $50 million Series D round of financing. New investors include Ally Bridge Group, Pura Vida Investments and Tao Capital Partners. Previous venture investors in Ultivue who also participated in the financing include ARCH Ventures, Northpond Ventures and Applied Ventures, LLC.
This additional funding will help Ultivue strengthen its position in the market, deliver innovative solutions to address the dynamic nature of tumor biology from precious tissue samples and to provide researchers and pathologists with the ability to fully realize the potential of tissue biomarkers within digital pathology workflows.